Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Lenvatinib and HAIC in advanced HCC
NCT06201065Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Dec 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06201065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06201065.